NASDAQ$RMTI
Rockwell Medical Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported financial results and a business update.
Rockwell Medical reported Q4 2020 revenues of $15.2 million compared to $15.5 million for the same quarter of the previous year. Net loss was $8.7 million, or $(0.09) basic and diluted net loss per share, compared to a net loss of $7.3 million, or $(0.11) basic and diluted net loss per share, for the same period in 2019. The company ended the year with $58.7 million in cash, cash equivalents and investments.
- Revenues were $15.2 million for the quarter ended December 31, 2020, compared to $15.5 million for the same period in 2019.
- Triferic revenue was $0.5 million for the quarter ended December 31, 2020.
- Net loss was $8.7 million, or $(0.09) basic and diluted net loss per share for the quarter ended December 31, 2020, compared to a net loss of $7.3 million, or $(0.11) basic and diluted net loss per share, for the same period in 2019.
- Cash, cash equivalents, and investments available-for-sale totaled $58.7 million as of December 31, 2020.
Headline financials
Revenue & EPS history
Rockwell Medical · Revenue · Quarterly
$15.2M
Forward guidance
Rockwell Medical is focused on the treatment of anemia in end-stage kidney disease and is working to expand the use of its FPC platform for the treatment of hospitalized patients with acute heart failure.
Tailwinds
- The FDA has accepted Rockwell Medical's proposed development strategy to pursue an approval via the 505(b)(1) pathway as a novel new drug application (NDA) for FPC for treatment of iron deficiency anemia (IDA) in adult patients in the home infusion setting.
- Rockwell Medical plans to initiate a clinical study during the second half of 2021 for FPC for treatment of IDA in adult patients in the home infusion setting.
- Rockwell Medical is exploring the use of its FPC platform for the treatment of hospitalized patients with acute heart failure.
- Jeil filed a New Drug Application for Triferic (dialysate) and Triferic AVNU in Korea.
- Wanbang Biopharmaceuticals enrolled the first patient in a pivotal Phase 3 trial in China.
Headwinds
- The company is facing challenges related to the COVID-19 pandemic, which is impacting its business and operating results.
- The company is subject to various risks and uncertainties, including those set forth in Rockwell Medical’s SEC filings.
- The company's actual results could be materially different from its forward-looking statements.
- The company's success is dependent on the commercialization of Triferic (dialysate) and Triferic AVNU.
- The company's success is dependent on the success and timing of international clinical trials for Triferic Dialysate.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
-3.1%
Avg return
Earnings day
-3.3%
Avg return
5 days after
-3.0%
Avg return
30 days after
38%
24 / 63 earnings
Positive
+28.2%
Q3 2022
Best reaction
-43.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -13.0% | -11.3% | — | |
| Q1 2026 | -3.6% | +2.8% | -18.2% | |
| Q3 2025 | -9.2% | -17.1% | -12.4% | |
| Q1 2025 | -6.4% | -9.8% | -11.6% | |
| Q4 2024 | -20.5% | -31.8% | -41.5% | |
| Q3 2024 | -43.4% | -49.2% | -55.5% | |
| Q2 2024 | +22.6% | +35.6% | +68.4% | |
| Q1 2024 | +0.6% | +4.1% | +8.2% | |
| Q4 2023 | +3.6% | +0.0% | -12.1% | |
| Q3 2023 | +12.2% | +5.1% | -11.2% | |
| Q2 2023 | -7.4% | -25.8% | -28.5% | |
| Q1 2023 | -4.5% | -3.7% | +71.8% | |
| Q4 2022 | +14.6% | +18.4% | +74.7% | |
| Q3 2022 | +28.2% | +19.4% | +0.0% | |
| Q2 2022 | +12.0% | +7.1% | -14.1% | |
| Q1 2022 | +3.0% | -17.3% | -34.7% | |
| Q4 2021 | -13.6% | -11.4% | -27.3% | |
| Q3 2021 | -7.7% | -7.7% | -21.2% | |
| Q2 2021 | -6.2% | -10.8% | -4.6% | |
| Q1 2021 | -2.2% | -4.3% | +0.0% | |
| Q4 2020 | +4.5% | -1.8% | -13.5% | |
| Q3 2020 | +1.1% | +5.6% | +33.7% | |
| Q2 2020 | +4.2% | +0.0% | -26.3% | |
| Q1 2020 | -4.7% | -12.9% | -9.0% | |
| Q4 2019 | -42.7% | -25.0% | -22.6% | |
| Q3 2019 | +5.4% | +12.4% | +23.7% | |
| Q2 2019 | -5.6% | +2.0% | +9.3% | |
| Q1 2019 | -7.5% | -11.9% | -25.6% | |
| Q4 2018 | +3.0% | +23.9% | +4.7% | |
| Q3 2018 | +8.9% | +12.3% | -16.2% | |
| Q2 2018 | -15.5% | -12.4% | -13.6% | |
| Q1 2018 | -2.5% | +5.8% | -8.8% | |
| Q4 2017 | -17.5% | -18.3% | -14.1% | |
| Q3 2017 | +9.6% | +11.6% | +3.4% | |
| Q2 2017 | -4.2% | -1.5% | -5.4% | |
| Q1 2017 | -1.2% | -9.1% | +9.3% | |
| Q4 2016 | +10.0% | +10.2% | +10.6% | |
| Q3 2016 | -20.5% | -3.5% | +27.3% | |
| Q2 2016 | -8.9% | -8.1% | -10.2% | |
| Q1 2016 | +19.7% | — | — | |
| Q4 2015 | -36.8% | — | — | |
| Q3 2015 | -10.5% | — | — | |
| Q2 2015 | +11.5% | — | — | |
| Q1 2015 | +12.9% | — | — | |
| Q4 2014 | -6.6% | — | — | |
| Q3 2014 | +5.7% | — | — | |
| Q2 2014 | +0.1% | — | — | |
| Q1 2014 | -8.5% | — | — | |
| Q3 2013 | -0.8% | — | — | |
| Q2 2013 | +0.6% | — | — | |
| Q1 2013 | -7.6% | — | — | |
| Q4 2012 | -19.9% | — | — | |
| Q3 2012 | -3.3% | — | — | |
| Q2 2012 | -6.4% | — | — | |
| Q1 2011 | -0.2% | — | — | |
| Q1 2012 | +1.0% | — | — | |
| Q4 2011 | -4.4% | — | — | |
| Q3 2011 | -9.3% | — | — | |
| Q3 2010 | -9.3% | — | — | |
| Q2 2011 | -0.1% | — | — | |
| Q2 2010 | -0.1% | — | — | |
| Q4 2010 | -1.4% | — | — | |
| Q1 2010 | +3.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro